Soki Kashima, MD, PhD
Associate Research ScientistAbout
Research
Publications
Featured Publications
Update on Biomarkers in Renal Cell Carcinoma.
Saliby R, Saad E, Kashima S, Schoenfeld D, Braun D. Update on Biomarkers in Renal Cell Carcinoma. American Society Of Clinical Oncology Educational Book 2024, 44: e430734. PMID: 38207251, DOI: 10.1200/edbk_430734.Peer-Reviewed Original ResearchThe Changing Landscape of Immunotherapy for Advanced Renal Cancer
Kashima S, Braun D. The Changing Landscape of Immunotherapy for Advanced Renal Cancer. Urologic Clinics Of North America 2023, 50: 335-349. PMID: 36948676, DOI: 10.1016/j.ucl.2023.01.012.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCytotoxic T Lymphocytes Regenerated from iPS Cells Have Therapeutic Efficacy in a Patient-Derived Xenograft Solid Tumor Model
Kashima S, Maeda T, Masuda K, Nagano S, Inoue T, Takeda M, Kono Y, Kobayashi T, Saito S, Higuchi T, Ichise H, Kobayashi Y, Iwaisako K, Terada K, Agata Y, Numakura K, Saito M, Narita S, Yasukawa M, Ogawa O, Habuchi T, Kawamoto H. Cytotoxic T Lymphocytes Regenerated from iPS Cells Have Therapeutic Efficacy in a Patient-Derived Xenograft Solid Tumor Model. IScience 2020, 23: 100998. PMID: 32259478, PMCID: PMC7188741, DOI: 10.1016/j.isci.2020.100998.Peer-Reviewed Original ResearchRegeneration of Tumor-Antigen-Specific Cytotoxic T Lymphocytes from iPSCs Transduced with Exogenous TCR Genes
Maeda T, Nagano S, Kashima S, Terada K, Agata Y, Ichise H, Ohtaka M, Nakanishi M, Fujiki F, Sugiyama H, Kitawaki T, Kadowaki N, Takaori-Kondo A, Masuda K, Kawamoto H. Regeneration of Tumor-Antigen-Specific Cytotoxic T Lymphocytes from iPSCs Transduced with Exogenous TCR Genes. Molecular Therapy Advances 2020, 19: 250-260. PMID: 33102617, PMCID: PMC7566080, DOI: 10.1016/j.omtm.2020.09.011.Peer-Reviewed Original ResearchFaithful preclinical mouse models for better translation to bedside in the field of immuno-oncology
Saito R, Kobayashi T, Kashima S, Matsumoto K, Ogawa O. Faithful preclinical mouse models for better translation to bedside in the field of immuno-oncology. International Journal Of Clinical Oncology 2019, 25: 831-841. PMID: 31407168, DOI: 10.1007/s10147-019-01520-z.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMyeloid cells mediate interferon-driven resistance to immunotherapy in advanced renal cell carcinoma
Bi K, Kashima S, Camp S, Meli K, Saad E, Titchen B, Labaki C, Bakouny Z, Pimenta E, Park J, Shannon E, Fu J, Xirenayi S, Horst J, Lum L, Ishizuka J, Choueiri T, Braun D, Van Allen E. Myeloid cells mediate interferon-driven resistance to immunotherapy in advanced renal cell carcinoma. Immunity 2025, 58: 2814-2829.e9. PMID: 41175876, PMCID: PMC12616721, DOI: 10.1016/j.immuni.2025.10.013.Peer-Reviewed Original Research
2026
IL-8 blockade enhances anti-PD-1 therapeutic activity in renal cell carcinoma in a next-generation patient-derived xenograft model
Sobu R, Kobayashi Y, Kashima S, Inoue T, Sumiyoshi T, Hamana H, Takeda M, Hiroshima Y, Seki S, Fujiyama N, Masuda K, Funakoshi Y, Okada S, Okubo K, Takahashi S, Sekine Y, Sato H, Kobayashi M, Yamamoto R, Nara T, Saito M, Narita S, Nanjo H, Kishi H, Watanabe T, Kawamoto H, Akamatsu S, Kobayashi T, Habuchi T. IL-8 blockade enhances anti-PD-1 therapeutic activity in renal cell carcinoma in a next-generation patient-derived xenograft model. IScience 2026, 29: 116386. PMID: 42338471, PMCID: PMC13285681, DOI: 10.1016/j.isci.2026.116386.Peer-Reviewed Original ResearchComprehensive analysis of oncological outcomes of radical cystectomy for non-muscle invasive bladder cancer
Sano T, Taoka R, Miki J, Saito R, Fukuokaya W, Matsui Y, Hatakeyama S, Kawahara T, Matsuda A, Kawai T, Kato M, Sazuka T, Urabe F, Kashima S, Naito H, Murakami Y, Miyake M, Daizumoto K, Matsushita Y, Hayashi T, Inokuchi J, Sugino Y, Shiga K, Yamaguchi N, Yamamoto S, Yasue K, Abe T, Nakanishi S, Hashine K, Fujii M, Nishihara K, Matsumoto H, Tatarano S, Wada K, Sekito S, Maruyama R, Nishiyama N, Nishiyama H, Kitamura H, Kobayashi T. Comprehensive analysis of oncological outcomes of radical cystectomy for non-muscle invasive bladder cancer. Scientific Reports 2026, 16: 16338. PMID: 41936674, PMCID: PMC13212721, DOI: 10.1038/s41598-026-46649-w.Peer-Reviewed Original ResearchAge-stratified outcomes of radical cystectomy for muscle-invasive bladder cancer: a nationwide multicenter study of 1867 patients in Japan
Kawai T, Miki J, Taoka R, Saito R, Fukuokaya W, Matsui Y, Fujii Y, Hatakeyama S, Kawahara T, Matsuda A, Kato M, Sazuka T, Sano T, Urabe F, Kashima S, Naito H, Murakami Y, Miyake M, Daizumoto K, Matsushita Y, Nakayama M, Matsumoto T, Sugino Y, Shiga K, Yamaguchi N, Yamamoto S, Yasue K, Abe T, Nakanishi S, Hashine K, Fujii M, Nishihara K, Kobayashi K, Tatarano S, Wada K, Sekito S, Maruyama R, Nishiyama N, Nishiyama H, Kitamura H, Kume H, Group T. Age-stratified outcomes of radical cystectomy for muscle-invasive bladder cancer: a nationwide multicenter study of 1867 patients in Japan. Japanese Journal Of Clinical Oncology 2026, 56: 475-483. PMID: 41543041, DOI: 10.1093/jjco/hyaf218.Peer-Reviewed Original Research
2025
Androgen‐Deprivation Therapy and Dietary Habits Influence the Gut Microbial Environment in Patients With High‐Risk Localized Prostate Cancer
Ishida M, Narita S, Sato H, Sekine Y, Kobayashi M, Kashima S, Yamamoto R, Numakura K, Saito M, Takahashi Y, Funahashi K, Yamauchi Y, Fukuda S, Habuchi T. Androgen‐Deprivation Therapy and Dietary Habits Influence the Gut Microbial Environment in Patients With High‐Risk Localized Prostate Cancer. The Prostate 2025, 86: 515-524. PMID: 41389040, DOI: 10.1002/pros.70109.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
News
News
- June 02, 2026
Yale Cancer Center Researchers and Trainees Present at 2026 ASCO Annual Meeting
- July 16, 2025
Yale Researchers Develop Novel Antibody-RNA Therapy for Resistant Cancers
- September 23, 2024Source: OncLive
Dr Kashima on T-Cell Phenotypes Associated With ICI Response/Resistance in RCC
- June 07, 2024
Yale Cancer Center Researchers and Trainees Present at ASCO
Get In Touch
Contacts
Locations
Center of Molecular and Cellular Oncology
Lab
300 George Street, Fl 6th Floor, Ste Suite 6109
New Haven, CT 06511